2023 Cisplatin Shortage Tied to Use of Alternatives for Head, Neck Cancer
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
TUESDAY, Oct. 1, 2024 -- The 2023 cisplatin shortage led to a shift in utilization to alternative therapies for head and neck cancer (HNC), resulting in significant cost increases, according to a study presented at the American Society of Clinical Oncology annual Quality Care Symposium, held from Sept. 27 to 28 in San Francisco.
Puneeth Indurlal, M.D., from the U.S. Oncology Network in The Woodlands, Texas, and colleagues assessed the effects of cisplatin shortage on the treatment of HNC at practices in the U.S. Oncology Network. Utilization trends and financial impact were assessed using drug administration data from medical records and claims for 26 practices prior to (July 2022 to January 2023), during (February to August 2023), and after (September 2023 to March 2024) the shortage period.
The researchers found that during the shortage period, cisplatin utilization for HNC decreased by 15 percent. The lowest utilization (a 60 percent decrease) occurred in June and July 2023. Alternative chemotherapy drugs for HNC saw increased use during the shortage, including carboplatin (40 percent increase), paclitaxel (24 percent), 5-fluorouracil (5.3 percent), and cetuximab (15 percent). Among existing cisplatin recipients, 10 percent were shifted to an alternative drug during the shortage period. While less acute of a shortage, 5-fluorouracil was also in short supply. Cisplatin volumes rebounded by 8 percent of preshortage use, while carboplatin use dropped below preshortage levels. Cetuximab use persisted at 12 percent higher. Based on Medicare average sale price, the average cost per administration was $18 for cisplatin, $14 for carboplatin, $16 for paclitaxel, $22 for 5-fluorouracil, and $2,607 for cetuximab. The increased use of cetuximab instead of cisplatin resulted in a 16 percent total cost increase, yielding a 144-fold increase in costs at the administration level, impacting both payer costs and patient cost-sharing amounts.
"The impacts of drug shortages on treatment decisions, guideline concordance, costs, and patient outcomes are apt for further investigation," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-10-02 12:00
Read more
- Parents, Clinicians Skeptical of Children's High Blood Pressure Readings
- CDC Reports Infant Death From Listeria Outbreak Tied to Ready-to-Eat Meats
- RSNA: Levothyroxine Tied to Bone Loss Over Time in Older Adults
- Many Women With Epilepsy Unaware of Seizure Meds' Risks to Pregnancy
- Higher Daily Step Count Linked to Lower Risk for Depression
- Family History of Mental Illness Tied to Aggression in Those With CTE
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions